SELLAS Life Sciences (SLS)

• Market cap: $177M
• 1 day: -0.59%
• 5 days: -10.64%
• 1 month: -2.89%
• 3 months: 7.01%
• 6 months: 55.56%
• Year to date: 57.01%
• 1 year: 37.7%
• 5 years: -37.78%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Employees: 15

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

6,736% more call options, than puts

Call options by funds: $18.5M | Put options by funds: $271K

567% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 6

280% more capital invested

Capital invested by funds: $15.4M [Q1] → $58.6M (+$43.2M) [Q2]

163% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 8

77% more funds holding

Funds holding: 44 [Q1] → 78 (+34) [Q2]

11.1% more ownership

Funds ownership: 15.73% [Q1] → 26.83% (+11.1%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7
• Avg. target: $7
• High target: $7

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy

$7

Buy Maintained

16 Jul 2025